Clinical trials: CTLA-4
Solid Tumor, Adult, EphA2 Overexpression
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with KRAS mutant peptide…
- Conditions
- Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C
- Trial name
- NCT05631899
- Testing
- KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
SCLC,Extensive Stage
A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer
A Phase Ib/II open label,international multicentre study to evaluate the efficacy and safety of anti-PD-1 and CTLA-4 bispecific antibody AK104 in combination with Chiauranib in Patients with Extensive Stage Small Cell Lung Cancer…
- Trial name
- NCT05505825
- Testing
- AK104 IV infusion；Chiauranib oral
- Where
- 7 sites in Australia, China
- Volunteers
- 36 people
- Sponsor
- Akeso
Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
This phase I/II trial studies the side effects of anti-CTLA4-NF monoclonal antibody (mAb) (BMS986218), nivolumab, and stereotactic body radiation therapy in treating patients with solid malignancies that has spread to other…
- Conditions
- Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm, Malignant Adrenal Gland Neoplasm, Metastatic Liver Carcinoma
- Trial name
- NCT04785287
- Testing
- Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma
Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
This is a single-center, single-arm, phase 2 clinical study testing a new neoadjuvant (pre-surgery) treatment for patients with locally advanced gastric cancer or gastroesophageal junction (GEJ) cancer.
- Trial name
- NCT07867392
- Testing
- Iparomlimab and Tuvonralimab (QL1706), nab-P-SOX（nab-paclitaxel, oxaliplatin, S-1）
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Colorectal Neoplasms
Combination Immunotherapy in Colorectal Cancer
This is a pilot study to see whether a combination of two investigational drugs that target the immune system can be given to people with colorectal cancer before surgically removing the tumor.
- Trial name
- NEST-1 (NCT05571293)
- Testing
- Botensilimab, Balstilimab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Advanced Solid Tumor
A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
This is an open label, dose escalation phase I study to evaluate the clinical safety, tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated Dose (MTD#, if any).
- Trial name
- NCT04338724
- Testing
- CS1002
- Where
- China
- Volunteers
- 6 people
- Sponsor
- CStone Pharmaceuticals
Melanoma
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
This phase I trial studies the side effects of adding anakinra and tocilizumab to standard treatment with nivolumab and ipilimumab and to see how well it works in treating melanoma patients who are 50 years of age or older.
- Trial name
- NCT07838974
- Testing
- Anakinra, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
Advanced Cancer
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in…
- Trial name
- NCT03459222
- Testing
- Relatlimab, Nivolumab, BMS-986205
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
- Trial name
- EMERGE (NCT03989362)
- Testing
- Vopratelimab, Ipilimumab
- Where
- 21 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Jounce Therapeutics, Inc.
CANCER, NOS
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced…
- Trial name
- NCT01750580
- Testing
- Lirilumab, Ipilimumab
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma
This is a Phase 1b, open-label study of immune checkpoints inhibitors Nivolumab+Ipilimumab administered in combination with the anti-TNF-α either Infliximab or Certolizumab, in patients with advanced melanoma.
- Trial name
- TICIMEL (NCT03293784)
- Testing
- Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab, Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Claudius Regaud
LRBA Deficiency, CTLA4 Haploinsufficiency
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies
Primary immune deficiencies (PID) are a group of chronic diseases characterized by recurrent infections. Apart from recurrent infections, in some of PIDs autoimmunity, allergy or malignancy could be accompanied to the diseases.
- Trial name
- NCT04377867
- Testing
- Abatacept Injection [Orencia]
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Marmara University
Abnormal Glucose Tolerance, Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM.
- Trial name
- NCT01773707
- Testing
- CTLA4-Ig (Abatacept)
- Where
- 17 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatocellular Carcinoma
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04444167
- Testing
- AK104, Lenvatinib
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Akeso
Advanced Solid Tumor
CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor
This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen…
- Trial name
- NCT03179007
- Testing
- Anti-CTLA-4/PD-1 expressing MUC1-CAR-T
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Cell Therapy Research Institute
CTLA4 Haploinsufficency, Chronic Cytopenia
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
Background: CTLA4 stands for cytotoxic T-lymphocyte antigen-4. It is a protein the body makes naturally to check its immune system from attacking itself.
- Trial name
- NCT03733067
- Testing
- abatacept
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Endometrial Cancer, Endometrial Carcinosarcoma
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
This study will test the safety and efficacy of the experimental drug called durvalumab with or without another experimental drug called tremelimumab in endometrial cancer.
- Conditions
- Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent
- Trial name
- NCT03015129
- Testing
- Durvalumab, Tremelimumab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Health Volunteer
Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects
This is a single-center, randomized, double-blind, does-escalation Phase I Clinical Study that aim to evaluate the tolerability, safety and PK Characteristics of recombinant humanized CTLA-4-FC fusion protein injection in Healthy…
- Trial name
- NCT05256719
- Testing
- Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg, Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg, Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Beijing VDJBio Co., LTD.
Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV
Intrathecal Double Checkpoint Inhibition
The objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small…
- Conditions
- Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV
- Trial name
- IT-IO (NCT05598853)
- Testing
- intrathecal nivolumab and intrathecal ipilimumab
- Where
- 3 sites in Switzerland
- Volunteers
- 26 people
- Sponsor
- University of Zurich